Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169421 | 1.00 | FNTA (0.36) | FNTAFNTBPDE10APSDADORA2A | |
| SCHEMBL23601379 | 0.94 | FNTA (0.36) | FNTAFNTBPSDABCG2 | |
| SCHEMBL29909845 | 0.94 | FNTA (0.36) | FNTAFNTBPSDABCG2 | |
| SCHEMBL29909025 | 0.92 | FNTA (0.37) | FNTAFNTBABCG2 | |
| SCHEMBL23577131 | 0.92 | FNTA (0.37) | FNTAFNTBABCG2 | |
| SCHEMBL23577097 | 0.91 | FNTA (0.36) | FNTAFNTB | |
| SCHEMBL29909228 | 0.90 | NT5E (0.33) | FNTAFNTBPDE10AABCG2ATM | |
| SCHEMBL23577262 | 0.90 | NT5E (0.33) | FNTAFNTBPDE10AABCG2ATM | |
| SCHEMBL23576895 | 0.89 | FNTA (0.37) | FNTAFNTBABCG2 | |
| SCHEMBL29909557 | 0.89 | FNTA (0.37) | FNTAFNTBABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | FNTA 968/4885FNTB 743/4885PDE10A 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.